AND DEVELOPMENT OF
THE WORLD IS IN URGENT NEED OF NOVEL DRUGS TO BATTLE VIRUSES
According to the World Health Organization, viral infections account for an estimated 60% of all infectious diseases globally and are a leading cause of morbidity and mortality worldwide.
In recent years, several high-profile viral outbreaks, such as Ebola, Zika, and COVID-19, have highlighted the urgent need for effective antiviral drugs to combat emerging viral threats.
A review published in Nature in 2019 noted that there are only a limited number of antiviral drugs available for clinical use, and that many of these drugs have limitations such as toxicity, poor efficacy, and the potential for the development of drug resistance.
The same review also noted that the development of new antiviral drugs is essential to address the threat of emerging viral diseases, as well as to combat the growing problem of drug-resistant viruses.
According to WHO, the emergence of drug-resistant strains of viruses such as influenza, HIV, and hepatitis C is a major concern, and the development of new antiviral drugs is crucial.
VIRUSES IN OTHER DISEASES
VIRAL INFECTIONS HAVE BEEN IMPLICATED IN CANCER, ALZHEIMER'S, PARKINSON'S, MULTIPLE SCLEROSIS AND OTHERS
The need for novel antivirals is not only about treating sudden pandemic infections. It is also about addressing the chronic viral infections that cause or at least trigger a range of diseases.
Viral infections are implicated in the development and progression of several serious diseases, including certain types of cancer, Alzheimer's, Parkinson's, and Multiple Sclerosis.
That is another reason why it is so important to develop new antivirals treatments. A whole range of serious diseases are caused by Human papillomavirus (HPV), hepatitis B and C virus, Epstein-Barr virus and many other viruses.
Preclinical tests show that our peptide Cov18A, developed to inhibit SARS-CoV-2, is able to inhibit the interaction between the peptide on the viral spike and the peptide on ACE2 receptor and in that way is able to inhibit infection with COVID-19 virus with up to 96% efficiency.
ADVANTAGES OF QBR PEPTIDES
Our RRM platform enables us to design peptides with very precise singular molecular interaction which does not affect other biological processes in the body. Therefore, we can potentially avoid unwanted side effects and create very safe treatments.
The other advantage of our approach is that our peptide, Cov18A, does not bind to COVID-19 spike protein nor to the ACE2 receptor protein.
The antiviral peptides that QBR can identify and design can be used to treat people who are ALREADY infected but also as PREVENTION of viral infections.
QBR’s peptides can be administered both as IV or a nasal spray.